Who are oxymetazoline-fluticasone propionate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dexmedetomidine-Dexamethasone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxymetazoline-fluticasone-propionate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

oxymetazoline-fluticasone propionate — Competitive Intelligence Brief

oxymetazoline-fluticasone propionate (oxymetazoline-fluticasone propionate) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nasal decongestant/corticosteroid combination. Area: Otolaryngology/Rhinology.

marketed Nasal decongestant/corticosteroid combination Alpha-2 adrenergic receptor; glucocorticoid receptor Otolaryngology/Rhinology Small molecule Live · refreshed every 30 min

Target snapshot

oxymetazoline-fluticasone propionate (oxymetazoline-fluticasone propionate) — Brian J Lipworth. This combination nasal spray uses a decongestant to reduce nasal swelling and a corticosteroid to suppress inflammatory responses in the nasal passages.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
oxymetazoline-fluticasone propionate TARGET	oxymetazoline-fluticasone propionate	Brian J Lipworth	marketed	Nasal decongestant/corticosteroid combination	Alpha-2 adrenergic receptor; glucocorticoid receptor
Dexmedetomidine-Dexamethasone	Dexmedetomidine-Dexamethasone	University of Chile	marketed	Alpha-2 adrenergic agonist / Corticosteroid combination	Alpha-2 adrenergic receptor; Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nasal decongestant/corticosteroid combination class)

Brian J Lipworth · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). oxymetazoline-fluticasone propionate — Competitive Intelligence Brief. https://druglandscape.com/ci/oxymetazoline-fluticasone-propionate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab